Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Saint-Herblain – page 24

606 clinical trials in Saint-Herblain, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint-Herblain at a glance
606
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

606 trials in Saint-Herblain

Open in trial search

Hepatocellular carcinoma+5

Not yet recruiting

DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:Dualitybio Inc.

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Interstitial lung disease+2

Not yet recruiting

Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Non-small cell lung cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merus B.V.

Non-small cell lung cancer metastatic

Not yet recruiting

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:AstraZeneca AB

Ischaemic stroke

Not yet recruiting

Comparing tenecteplase and mechanical clot removal versus mechanical clot removal alone for adults with a large ischemic stroke

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Assistance Publique Hopitaux De Paris

Primary bilateral macronodular adrenal hyperplasia

Not yet recruiting

Study of the effect of metyrapone in patients with mild Cushing syndrome caused by primary bilateral macronodular adrenal hyperplasia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Metyrapone
  • Sponsor:Assistance Publique Hopitaux De Paris

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Glioblastoma

Not yet recruiting

Phase 3 Randomized Study of Niraparib Tosilate Monohydrate vs. Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Neurotrials LLC

Bone sarcoma

Not yet recruiting

Study of regorafenib as maintenance treatment after first-line therapy in patients with bone sarcomas without remaining disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Regorafenib
  • Sponsor:Centre Leon Berard

Cervical dysplasia

Not yet recruiting

Testing HPV Vaccine to Prevent Return of Precancerous Lesions in Patients Treated for High-Grade Abnormal Cell Changes Caused by HPV

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:POLYSORBATE 80
  • Sponsor:Institut Gustave Roussy

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Saint-Herblain

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for breast cancer, lung cancer, and gastric cancer. Research includes novel therapeutic approaches targeting specific cancer types.

  • Triple-negative breast cancer interventions
  • Non-small cell lung cancer therapies
  • Gastrointestinal cancer treatments

Several trials are evaluating new antibody-drug conjugates and combination therapies for metastatic diseases.

02 Neurological Disorders

Studies targeting various neurological conditions, with emphasis on frontotemporal dementia and multiple sclerosis. Research focuses on innovative therapeutic approaches and disease-modifying treatments.

  • Dementia progression studies
  • Multiple sclerosis treatments
  • Sleep disorder interventions

Trials include evaluation of novel antibodies and assessment of long-term treatment efficacy.

03 Cardiovascular Studies

Comprehensive research into heart failure prevention, pulmonary hypertension, and cardiac rhythm disorders. Studies focus on innovative therapeutic approaches and preventive measures.

  • Heart failure prevention strategies
  • Pulmonary hypertension treatments
  • Cardiac rhythm management

Research includes long-term safety assessments and combination therapy evaluations.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.